No Data
Jiangsu Hengrui Pharmaceuticals (600276.SH): A total of 5.898 million shares have been repurchased.
On March 11, Gelonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that as of March 11, 2025, the company has cumulatively repurchased 5,898,044 shares through centralized bidding, accounting for 0.09% of the company's total share capital. The highest transaction price was 57.01 yuan/share, the lowest was 39.00 yuan/share, and the total amount paid was 250,613,211.80 yuan (excluding transaction fees). The aforementioned repurchase complies with relevant laws and regulations and the company's established share repurchase plan.
Hengrui Medicine's Subsidiaries Get Nod to Trial Anti-Tumor Drugs
Jiangsu Hengrui Pharmaceuticals (600276.SH): Bought back a total of 5.53 million shares.
On March 4, Gelinghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that as of February 28, 2025, the company had repurchased a total of 5,530,044 shares through centralized bidding Trade, accounting for 0.09% of the company's total share capital. The highest transaction price was 57.01 yuan/share, and the lowest price was 39.00 yuan/share, with a total amount paid of 233,902,752.60 yuan (excluding transaction fees). The above repurchase complies with relevant laws and regulations as well as the company's predetermined share repurchase plan.
Jiangsu Hengrui Medicine Obtains Clinical Trial Approvals for Two Injectable Drugs; Shares Down 3%
Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-A2009 injection and Adebali monoclonal antibody injection have obtained approval for clinical trials.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, its subsidiary Suzhou Shengdiya Biomedical Co., Ltd...
Hengrui Medicine Unit Gets Clinical Trial Nod for Hyperlipidemia Drug
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
